Source: medusapath.com, by Lily Tanner. AI-generated summary by biochip.com, published . Not independently reviewed.
Key takeaways
- CHIP variants can occur in TP53, KRAS, BRCA2, ATM, IDH1, IDH2 and JAK2, genes commonly assessed on solid-tumor panels.
- DNMT3A accounts for roughly half of CHIP mutations, while TET2 and ASXL1 are also frequent.
- The source gives no specific workflow or validation method for distinguishing CHIP variants from tumor-derived DNA.
A molecular diagnostics commentary warns that mutations from clonal hematopoiesis of indeterminate potential, or CHIP, can be mistaken for drug-relevant mutations shed by a solid tumor into blood. That problem matters because liquid biopsy tests examine cell-free DNA, fragments of genetic material circulating in plasma, and not every altered fragment comes from cancer in an organ such as the lung, colon, or breast. CHIP arises when a blood-forming stem cell acquires a mutation and gradually produces a population of blood cells carrying it. The source highlights an uncomfortable overlap: genes frequently mutated in CHIP also appear on solid-tumor next-generation sequencing panels as cancer drivers or treatment targets. A result in TP53, KRAS, BRCA2, ATM, IDH1, IDH2, or JAK2 may therefore look actionable before its biological origin has been established. The commentary argues that this can distort reflex testing, treatment matching, and clinical-trial enrollment. It also stresses that CHIP is not simply laboratory noise, because people with CHIP have an approximately 10-fold higher long-term risk of hematologic malignancy than age-matched controls. The central challenge is to avoid assigning a blood-cell mutation to a solid tumor while recognizing that the finding may still carry clinical significance.
Why blood can tell two stories
Liquid biopsy is often described as a way to sample a tumor without taking tissue directly from it. In practice, it is more like listening to a crowded room through a wall: the assay can detect genetic signals in the bloodstream, but it must determine which cell population produced each signal.
Cell-free DNA can originate from many dying or damaged cells. In a person with a solid tumor, some fragments may indeed come from tumor cells, while others can come from normal tissues and blood cells. CHIP makes this distinction especially consequential because mutated blood-cell clones can contribute DNA carrying variants that resemble tumor-associated findings.
The genes create the trap
The source identifies DNMT3A as accounting for roughly half of CHIP mutations, with TET2 and ASXL1 completing the most frequent trio. These genes are therefore central to the basic recognition problem: a variant detected in plasma may reflect a clone in the blood-forming system rather than a solid malignancy.
But the overlap extends beyond those common CHIP genes. The commentary says CHIP variants can also occur in TP53, KRAS, BRCA2, ATM, IDH1, IDH2, and JAK2, genes that are routinely treated as oncogenic or potentially actionable on solid-tumor sequencing panels. That overlap is what turns a technical interpretation issue into a possible clinical error.
When actionable does not mean tumor-derived
An actionable mutation is generally a genetic alteration that could influence drug selection, trigger further testing, or support eligibility for a clinical trial. The source's concern is not that these genes lack importance in cancer. It is that detecting a variant in one of them through plasma testing does not, on its own, prove that the solid tumor carries it.
Consider a mutation call as a label on a package, not proof of who sent it. The gene name may correctly identify the mutation, yet the laboratory still needs to establish whether the DNA originated in the tumor under evaluation or in a blood-cell clone. If that origin is misassigned, a result may send clinicians toward tumor-directed decisions on an incomplete premise.
Why this affects the laboratory workflow
The commentary describes these findings as the exact alterations that can prompt reflex testing, drug matching, and trial enrollment. A false-positive tumor driver call can therefore propagate through the diagnostic process, shaping follow-up work and potentially the options discussed with a patient.
This is why the source frames CHIP as a recurring bench-level concern rather than an obscure edge case. The diagnostic laboratory is being asked to interpret not only whether a variant is detectable, but also what biological compartment it represents. That distinction is fundamental whenever a blood-based assay is used to characterize a solid tumor.
CHIP is not merely a false positive
The source adds a second layer of complexity: individuals with CHIP have approximately a 10-fold increased risk of eventually developing a hematologic malignancy compared with age-matched controls. Hematologic malignancies are cancers of blood-forming tissues, including diseases that arise in bone marrow and blood cells.
That statistic does not mean that a liquid-biopsy finding caused a later blood cancer. As the commentary emphasizes, the CHIP clone was already present. Nor does it establish that every person with CHIP will develop a hematologic malignancy, but it means a variant dismissed as unrelated to a solid tumor can still point to a clinically relevant process in another organ system.
Why This Matters
The article's key message is a matter of diagnostic precision. If laboratories treat every plasma-detected alteration in a cancer-associated gene as tumor-derived, they risk confusing two biologically distinct conditions: a solid tumor and age-associated clonal expansion in blood-forming cells.
The opposite mistake also deserves attention. Simply excluding a suspected CHIP-associated variant as assay interference may obscure information about the patient's hematologic risk. The source argues that recognizing CHIP protects the integrity of the tumor assay while preserving the possibility that the result has a different medical meaning.
What careful interpretation requires
The source does not prescribe a specific testing algorithm, validation method, or clinical management pathway. It instead spotlights the interpretive problem facing molecular diagnostics teams when mutations in the same genes can arise from different tissues and have very different implications.
For clinicians and laboratories, the practical lesson is to ask a basic question before a mutation drives an oncology decision: what is the most likely source of this DNA? As liquid biopsy becomes part of more cancer workflows, answering that question clearly will remain essential to separating tumor biology from blood-cell clonal biology, and to communicating what a result can and cannot establish.